Medical Economics January 20, 2025
Todd Shryock

Key Takeaways

  • The Farapulse PFA System showed a 2.3% adverse event rate and 63.5% effectiveness in the Advantage AF study for persistent AF.
  • Symptomatic AF recurrence-free rates reached 91.8% for experienced physicians, with no major complications reported.
  • The Watchman FLX device reduced non-procedural bleeding by 44% and 62% for concomitant and sequential implantation, respectively, compared to oral anticoagulants.
  • Boston Scientific aims to improve AF patient outcomes by providing safer, more effective treatment options, enhancing quality of life and long-term health.

Boston Scientific showcases promising data on heart treatments at AF Symposium 2025

Boston Scientific Corp highlighted its advancements in treating atrial fibrillation with its Farapulse Pulsed Field Ablation System and the Watchman FLX Left Atrial Appendage Closure Device...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Medical Devices, Provider
Related Articles:
FIRE1 Secures $120 Million Financing to Revolutionize Heart Failure Care
Medical Device IPOs Could Revive Health Tech Listings
BD to expand production of critical medical devices
Boston Scientific to acquire Bolt Medical for up to $664 million
Is Medtronic On the Cusp of Rewriting Its Own Story in Renal Denervation?

Share This Article